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INTRODUCTION
Acquired or innate resistance to chemotherapy poses a
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Include Disvussion
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significant challenge in the treatment of head and neck

The concentration of cisplatin required to kill 50% of cells (IC50) was

squamous cell carcinoma (HNSCC) resulting in relapse,

determined for each of the five HPV+ HNSCC lines.

Chemotherapy resistance occurs when small populations of
cancer cells evade the cytotoxicity of cancer drugs and are
able to survive and propagate.
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metastasis and increased mortality.
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TREATMENT CONDITIONS

cisplatin.

500,000 of each of the cell lines were plated in three flasks and treated 2x,

Additionally, the genetic profile of the resistant cells will

5x, and 10x their cisplatin IC50 concentrations respectively.

be explored by sequencing, analysis, and comparison

The
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with genome-wide CRISPR knockout screening data.
We aim to characterize the genes that may underlie
the

molecular

and

genetic

basis

of

cisplatin

resistance in HPV+ HNSCC.

CONCLUSION
The generation of the cisplatin resistant cell lines will
allow

us

to

explore

the

underlying

mechanism

of

cisplatin resistance in HPV+ cell lines.
Clinically,

it

will

potentially

improve

the

treatment

regimen of patients with treatment resistant diseases.
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RATIONALE
The molecular and genetic basis of cisplatin resistance in HPVpositive HNSCC is not well-defined.

OBJECTIVE
The purpose of this experiment is to generate in-vitro models of

PRELIMINARY RESULTS
The IC50 values for each of the cell lines is as follows:

UWO23: 2.77 μM
UWO37: 1.90 μM
UMSCC47: 3.22μM
UPCI:SCC90: 1.51 μM
93VU147T: 2.21 μM

cisplatin resistance in five HPV+ HNSCC cell lines for further

The result indicates UMSCC47 cells are most resistant to

studies.

cisplatin while UPCI:SCC90 cells are the most sensitive.
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